Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect
- PMID: 2481029
Opioid drug discrimination in humans: stability, specificity and relation to self-reported drug effect
Abstract
Non-dependent volunteers with histories of opioid use were trained in a three-choice drug-discrimination procedure to discriminate the effects of i.m. saline, hydromorphone hydrochloride (3 mg/70 kg) and pentazocine lactate (45 mg/70 kg). In daily sessions, monetary reinforcement was contingent upon correctly identifying by letter code, the drug administered; measures of drug discrimination included an operant procedure and a qualitative and a quantitative choice procedure. Drug effects were assessed concurrently on self reports and physiological indices. After acquisition of the discrimination, subjects were tested for generalization to: 1) a range of doses of the training drugs, 2) p.o. doses of the training drugs and 3) novel drugs. The discrimination was readily learned and all three discrimination measures were comparable. Discrimination performance, as well as self reports and physiological effects, remained stable over the course of the study, suggesting that tolerance did not develop in the daily session procedure. Testing with a range of doses of the training drugs resulted in dose-related effects in discrimination performance, physiological effects and self-reported drug effect. Oral doses of the training drugs resulted in partial generalization to the i.m. training doses, compatible with the attenuated subjective effects of the p.o. doses. Novel drugs (d-amphetamine, 10-20 mg p.o.; Lorazepam, 2-4 mg p.o.; and secobarbital, 100-200 mg p.o.) did not generalize to hydromorphone, but showed partial generalization to both pentazocine and saline. In general, drug-discrimination performance paralleled the patterns of self reports.
Similar articles
-
Three-choice drug discrimination in opioid-dependent humans: hydromorphone, naloxone and saline.J Pharmacol Exp Ther. 1987 Dec;243(3):1002-9. J Pharmacol Exp Ther. 1987. PMID: 2447262
-
Drug discrimination assessment of agonist-antagonist opioids in humans: a three-choice saline-hydromorphone-butorphanol procedure.J Pharmacol Exp Ther. 1994 Oct;271(1):48-60. J Pharmacol Exp Ther. 1994. PMID: 7525929
-
Discrimination of agonist-antagonist opioids in humans trained on a two-choice saline-hydromorphone discrimination.J Pharmacol Exp Ther. 1992 Apr;261(1):62-71. J Pharmacol Exp Ther. 1992. PMID: 1373189
-
Assessment of buprenorphine in a drug discrimination procedure in humans.NIDA Res Monogr. 1992;121:28-37. NIDA Res Monogr. 1992. PMID: 1406908 Review.
-
[Recent developments in the pharmacology and clinical use of pentazocine].Masui. 1991 Jul;40(7):1037-41. Masui. 1991. PMID: 1920775 Review. Japanese.
Cited by
-
Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype-genotype assessment.Addict Biol. 2024 Jan;29(1):e13355. doi: 10.1111/adb.13355. Addict Biol. 2024. PMID: 38221808 Free PMC article. Clinical Trial.
-
Acute behavioral and cardiac effects of cocaine and alcohol combinations in humans.Psychopharmacology (Berl). 1993;111(3):285-94. doi: 10.1007/BF02244943. Psychopharmacology (Berl). 1993. PMID: 7870965 Clinical Trial.
-
A procedure for studying the within-session onset of human drug discrimination.J Exp Anal Behav. 1994 Mar;61(2):181-9. doi: 10.1901/jeab.1994.61-181. J Exp Anal Behav. 1994. PMID: 8169567 Free PMC article. Clinical Trial.
-
Emergent equivalence relations between interoceptive (drug) and exteroceptive (visual) stimuli.J Exp Anal Behav. 1992 Jul;58(1):9-18. doi: 10.1901/jeab.1992.58-9. J Exp Anal Behav. 1992. PMID: 1645104 Free PMC article. Clinical Trial.
-
Discriminative Stimulus Properties of Opioid Ligands: Progress and Future Directions.Curr Top Behav Neurosci. 2018;39:175-192. doi: 10.1007/7854_2016_9. Curr Top Behav Neurosci. 2018. PMID: 27225498 Review.